geometrybase
8a0dfd88f0
Request: - Add extracted PDF text generation to the archivist workflow as a standard step. Changes: - Run PDF text extraction automatically for newly archived HKEX PDF sources. - Make the PDF text extractor incremental and manifest-preserving. - Document extracted-text handling in the archivist skill and README. - Mark generated extracted text as no-diff data evidence. - Backfill extracted text for all archived PDF source references. Verification: - Ran git diff --cached --check. - Ran .venv/bin/python -m py_compile scripts/extract_pdf_text.py scripts/archive_hkex_documents.py. - Ran full PDF extraction, then confirmed an incremental rerun skips unchanged files. - Verified 557 PDF source_refs, 557 manifest rows, all status ok, and zero missing text/hash/path issues. Next useful context: - HKEX HTML notices and Yahoo JSON market data remain under data/raw and are not expected in data/extracted_text.
1157 lines
35 KiB
Plaintext
1157 lines
35 KiB
Plaintext
--- page 1 ---
|
||
1
|
||
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange ”)
|
||
and Hong Kong Securities Clearing Company Limited ( “HKSCC ”) take no responsibility for the contents of this
|
||
announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability
|
||
whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this
|
||
announcement.
|
||
Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those
|
||
defined in the prospectus dated May 19, 2025 (the “Prospectus ”) of PegBio Co., Ltd.(ᔼᖹ (ψ)ࠢ
|
||
ʮ̡) (the “Company ”).
|
||
This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase
|
||
or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the Prospectus
|
||
for detailed information about the Global Offering described below before deciding whether or not to invest in
|
||
the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the
|
||
information provided in the Prospectus.
|
||
This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States
|
||
(including its territories and possessions, any state of the United States and the District of Columbia). This
|
||
announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities
|
||
in the United States or in any other jurisdictions. The securities mentioned herein have not been, and will not be,
|
||
registered under the United States Securities Act of 1933 as amended from time to time (the “U.S. Securities Act ”) or
|
||
securities law of any state or other jurisdiction of the United States. The securities may not be offered, sold, pledged
|
||
or otherwise transferred within the United States except pursuant to an exemption from the registration requirements
|
||
of the U.S. Securities Act and in compliance with any applicable state securities laws. The securities are being offered
|
||
and sold outside the United States in offshore transactions in compliance with Regulation S under the U.S. Securities
|
||
Act. There will be no public offer of securities in the United States.
|
||
Potential investors of the Offer Shares should note that the Sponsor-OC (for itself and on behalf of the Hong Kong
|
||
Underwriters) shall be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon
|
||
the occurrence of any of the events set out in the section headed “Underwriting { Underwriting Arrangements and
|
||
Expenses { Hong Kong Public Offering { Grounds for Termination ” in the Prospectus at any time prior to 8:00 a.m.
|
||
on the Listing Date.
|
||
|
||
|
||
--- page 2 ---
|
||
2
|
||
PegBio Co., Ltd.
|
||
ᔼᖹ (ψ )ʮ̡
|
||
(A joint stock company incorporated in the People ’s Republic of China with limited liability)
|
||
GLOBAL OFFERING
|
||
Number of Offer Shares under
|
||
the Global Offering
|
||
: 19,283,500 H Shares
|
||
Number of Hong Kong Offer Shares : 9,642,000 H Shares (as adjusted after
|
||
reallocation)
|
||
Number of International Offer Shares : 9,641,500 H Shares (as adjusted after
|
||
reallocation)
|
||
Final Offer Price : HK$15.60 per Offer Share, plus
|
||
brokerage of 1.0%, SFC transaction
|
||
levy of 0.0027%, AFRC transaction
|
||
levy of 0.00015% and Hong Kong
|
||
Stock Exchange trading fee of
|
||
0.00565%
|
||
Nominal value : RMB1.00 per H Share
|
||
Stock code : 2565
|
||
Sole Sponsor, Overall Coordinator, Joint Global Coordinator,
|
||
Joint Bookrunner and Joint Lead Manager
|
||
Overall Coordinators, Joint Global Coordinators,
|
||
Joint Bookrunners and Joint Lead Managers
|
||
Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers
|
||
Joint Bookrunners and Joint Lead Managers
|
||
⳪暲@:9)
|
||
|
||
|
||
--- page 3 ---
|
||
3
|
||
PEGBIO CO., LTD./ʮ̡
|
||
ANNOUNCEMENT OF ALLOTMENT RESULTS
|
||
Unless otherwise defined herein, capitalized terms used in this announcement shall have the same
|
||
meanings as those defined in the prospectus dated May 19, 2025 (the “Prospectus ”) issued by
|
||
PegBio Co., Ltd. (ʮ̡) (the “Company ”).
|
||
Warning: In view of high concentration of shareholding in a small number of H
|
||
Shareholders, H Shareholders and prospective investors should be aware that the price of
|
||
the H Shares could move substantially even with a small number of H Shares traded and
|
||
should exercise extreme caution when dealing in the H Shares.
|
||
SUMMARY
|
||
Company Information
|
||
Stock code 2565
|
||
Stock short name PEGBIO CO-B
|
||
Dealings commencement date May 27, 2025*
|
||
* see note at the end of the announcement
|
||
Price Information
|
||
Final Offer Price HK$15.60
|
||
Offer Price Adjustment exercised N/A
|
||
Offer Shares and Share Capital
|
||
Number of Offer Shares 19,283,500
|
||
Number of Offer Shares in Hong Kong Public
|
||
Offering (as adjusted after reallocation)
|
||
9,642,000
|
||
Number of Offer Shares in International Offering (as
|
||
adjusted after reallocation)
|
||
9,641,500
|
||
Number of issued Shares upon Listing 385,955,532
|
||
Over-allocation
|
||
Number of Offer Shares over-allocated –
|
||
Proceeds
|
||
Gross proceeds (Note) HK$300.8 million
|
||
Less: Estimated listing expenses payable based on
|
||
Final Offer Price
|
||
HK$(69.1) million
|
||
Net proceeds HK$231.8 million
|
||
Note: Gross proceeds refer to the amount which the Company is entitled to receive. For details of the use of
|
||
proceeds, please refer to the section headed “Future Plans and Use of Proceeds ” in the Prospectus.
|
||
|
||
|
||
--- page 4 ---
|
||
4
|
||
ALLOTMENT RESULTS DETAILS
|
||
HONG KONG PUBLIC OFFERING
|
||
No. of valid applications 49,627
|
||
No. of successful applications 10,396
|
||
Subscription level 743.78 times
|
||
Claw-back triggered Yes
|
||
No. of Offer Shares initially available under the Hong Kong Public
|
||
Offering
|
||
1,928,500
|
||
No. of Offer Shares reallocated from the International Offer (claw-
|
||
back)
|
||
7,713,500
|
||
Final no. of Offer Shares under the Hong Kong Public Offering (as
|
||
adjusted after reallocation)
|
||
9,642,000
|
||
% of Offer Shares under the Hong Kong Public Offering to the
|
||
Global Offering
|
||
approximately 50.0%
|
||
Note: For details of the final allocation of H Shares to the Hong Kong Public Offering, investors can refer to
|
||
www.eipo.com.hk/eIPOAllotment to perform a search by identification number or www.eipo.com.hk/eIPOAllotment
|
||
for the full list of allottees.
|
||
INTERNATIONAL OFFERING
|
||
No. of placees 115
|
||
Subscription Level 1.13 times
|
||
No. of Offer Shares initially available under the International
|
||
Offering
|
||
17,355,000
|
||
No. of Offer Shares reallocated to the Hong Kong Public Offering
|
||
(claw-back)
|
||
7,713,500
|
||
Final no. of Offer Shares under the International Offering (as
|
||
adjusted after reallocation)
|
||
9,641,500
|
||
% of Offer Shares under the International Offering to the Global
|
||
Offering
|
||
approximately 50.0%
|
||
|
||
|
||
--- page 5 ---
|
||
5
|
||
The Directors confirm that, to the best of their knowledge, information and belief, (i) none of the
|
||
Offer Shares subscribed by the placees and the public have been financed directly or indirectly
|
||
by the Company, any of the Directors, Supervisors, chief executive of the Company, substantial
|
||
Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective
|
||
close associates; and (ii) none of the placees and the public who have purchased the Offer Shares
|
||
are accustomed to taking instructions from the Company, any of the Directors, Supervisors, chief
|
||
executive of the Company, substantial Shareholders, existing Shareholders of the Company or any
|
||
of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting
|
||
or other disposition of H Shares registered in his/her/its name or otherwise held by him/her/it.
|
||
The placees in the International Offering include the following:
|
||
Cornerstone Investor
|
||
Investor (Note)
|
||
No. of Offer
|
||
Shares
|
||
allocated
|
||
% of Offer
|
||
Shares
|
||
% of total
|
||
issued H
|
||
Shares after
|
||
the Global
|
||
Offering
|
||
% of total
|
||
issued
|
||
Shares after
|
||
the Global
|
||
Offering
|
||
Existing
|
||
Shareholders
|
||
or their close
|
||
associates
|
||
Yizekangrui
|
||
Medical (HK)
|
||
Limited ( ूዣ
|
||
ੰᔼᖹ (࠰
|
||
ಥ)ʮ̡ )
|
||
(“Yizekangrui ”) 9,584,500 49.70% 3.43% 2.48% No
|
||
Total 9,584,500 49.70% 3.43% 2.48%
|
||
Note: For further details of the Cornerstone Investor, please refer to the section headed “Cornerstone Investor ” in
|
||
the Prospectus.
|
||
|
||
|
||
--- page 6 ---
|
||
6
|
||
LOCK-UP UNDERTAKINGS
|
||
Existing Shareholders
|
||
Name
|
||
Number
|
||
of Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued H
|
||
Shares subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued Shares
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (Note 1)
|
||
Concert Parties (as defined below) (Note 2)
|
||
Dr. Michael Min XU (Note 2) 58,081,874
|
||
(including
|
||
17,424,562 H
|
||
Shares)
|
||
6.24% 15.05% May 26, 2026
|
||
Shanghai Sujie Business Management
|
||
Consulting Partnership (Limited
|
||
Partnership) ( ɪऎᘽቪΆุ၍ଣፔ༔Υྫ
|
||
Άุ(Υྫ)) (“Shanghai Sujie ”) (Note 2)
|
||
29,175,230 H
|
||
Shares
|
||
10.45% 7.56% May 26, 2026
|
||
Dr. Yuhong XU (ࠀNote 2) 6,810,871 H
|
||
Shares
|
||
2.44% 1.76% May 26, 2026
|
||
Dr. Xiangjun ZHOU (Note 2) 6,268,463 H
|
||
Shares
|
||
2.25% 1.62% May 26, 2026
|
||
Sub-total 100,336,438
|
||
(including
|
||
59,679,126 H
|
||
Shares)
|
||
21.38% 26.00%
|
||
|
||
|
||
--- page 7 ---
|
||
7
|
||
Name
|
||
Number
|
||
of Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued H
|
||
Shares subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued Shares
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (Note 1)
|
||
Mingly (Note 3)
|
||
Mingly China Growth Fund, L.P.
|
||
(“Mingly ”) (Note 3)
|
||
34,852,074
|
||
(including
|
||
17,426,037 H
|
||
Shares)
|
||
6.24% 9.03% May 26, 2026
|
||
YuanBio Venture Capital ( ʩ͛௴ҳ ) (Note 4)
|
||
SIP Sungent BioVenture Capital
|
||
Investment Partnership (Limited
|
||
Partnership) (ʩ͛
|
||
௴ุҳ༟Άุ (Υྫ )) ( “SIP
|
||
BioVC ”) (Note 4)
|
||
11,339,959 H
|
||
Shares
|
||
4.06% 2.94% May 26, 2026
|
||
SIP Sungent Venture Capital Investment
|
||
Partnership II (Limited Partnership) ( ᘽψ
|
||
ʩɚಂ௴ุҳ༟Άุ (ࠢ
|
||
Υྫ)) (“SIP VC II ”) (Note 4)
|
||
3,201,273 H
|
||
Shares
|
||
1.15% 0.83% May 26, 2026
|
||
YuanBio Venture Capital L.P.
|
||
(“YuanBio ”) (Note 4)
|
||
3,113,437 H
|
||
Shares
|
||
1.12% 0.81% May 26, 2026
|
||
SIP Sungent Venture Capital Investment
|
||
Partnership III (Limited Partnership) ( ᘽ
|
||
ʩɧಂ௴ุҳ༟Άุ (Ϟ
|
||
Υྫ)) (“SIP VC III ”) (Note 4)
|
||
2,646,354 H
|
||
Shares
|
||
0.95% 0.69% May 26, 2026
|
||
Sub-total 20,301,023 H
|
||
Shares
|
||
7.27% 5.26%
|
||
|
||
|
||
--- page 8 ---
|
||
8
|
||
Name
|
||
Number
|
||
of Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued H
|
||
Shares subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued Shares
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (Note 1)
|
||
Tigermed (Note 5)
|
||
Hangzhou Tigermed Equity Investment
|
||
Partnership (Limited Partnership) (
|
||
ᛆҳ༟ΥྫΆุ (Υྫ ))
|
||
(“Hangzhou Tigermed ”) (Note 5)
|
||
9,634,137 H
|
||
Shares
|
||
3.45% 2.50% May 26, 2026
|
||
Hongkong Tigermed Co., Limited (࠰
|
||
ʮ̡ ) (“Tigermed
|
||
HK”) (Note 5)
|
||
4,247,204 H
|
||
Shares
|
||
1.52% 1.10% May 26, 2026
|
||
Hangzhou Taiyu Phase IV Venture
|
||
Capital Partnership (Limited Partnership)
|
||
(ψइᚑ̬ಂ௴ุҳ༟ΥྫΆุ (ࠢ
|
||
Υྫ)) (“Hangzhou Taiyu ”) (Note 5)
|
||
1,817,998 H
|
||
Shares
|
||
0.65% 0.47% May 26, 2026
|
||
Sub-total 15,699,339 H
|
||
Shares
|
||
5.62% 4.07%
|
||
Yingke PE (Note 6)
|
||
Pingtan Yingke Shengxin Venture Capital
|
||
Partnership (Limited Partnership) ( ̻ᆐ
|
||
ସ㒥௴ุҳ༟ΥྫΆุ (Υྫ ))
|
||
(“Pingtan Yingke ”) (Note 6)
|
||
8,468,396
|
||
Unlisted
|
||
Shares
|
||
– 2.19% May 26, 2026
|
||
Zibo Yingke Jiyun Venture Capital
|
||
Partnership (Limited Partnership) ( ௹
|
||
Λ༶௴ุҳ༟ΥྫΆุ (Υྫ ))
|
||
(“Zibo Yingke ”) (Note 6)
|
||
4,071,314
|
||
Unlisted
|
||
Shares
|
||
– 1.05% May 26, 2026
|
||
Sub-total 12,539,710
|
||
Unlisted
|
||
Shares
|
||
– 3.25%
|
||
Qianhai (Note 7)
|
||
Qianhai Equity Investment Fund (Limited
|
||
Partnership) (ږ( Υ
|
||
ྫ)) (“Qianhai FoF ”) (Note 7)
|
||
8,290,415 H
|
||
Shares
|
||
2.97% 2.15% May 26, 2026
|
||
Zhongyuan Qianhai Equity Investment
|
||
Fund (Limited Partnership) (ٰ
|
||
ږ( Υྫ )) ( “Zhongyuan
|
||
Qianhai ”) (Note 7)
|
||
3,562,399 H
|
||
Shares
|
||
1.28% 0.92% May 26, 2026
|
||
|
||
|
||
--- page 9 ---
|
||
9
|
||
Name
|
||
Number
|
||
of Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued H
|
||
Shares subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued Shares
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (Note 1)
|
||
Sub-total 11,852,814 H
|
||
Shares
|
||
4.25% 3.07%
|
||
Mr. Jian CHEN ( ᄉ) and his controlled entity (Note 8)
|
||
Beijing Agile Way Consulting Co., Ltd.
|
||
(ʮ̡ ) (“Beijing
|
||
Agile ”) (Note 8)
|
||
4,246,946
|
||
(including
|
||
350,000 H
|
||
Shares)
|
||
0.13% 1.10% May 26, 2026
|
||
Mr. Jian CHEN ( ᄉ) (Note 8) 1,817,998
|
||
(including
|
||
650,000 H
|
||
Shares)
|
||
0.23% 0.47% May 26, 2026
|
||
Sub-total 6,064,944
|
||
(including
|
||
1,000,000 H
|
||
Shares)
|
||
0.36% 1.57%
|
||
Other Pre-IPO Investors (Note 9)
|
||
True Wing Limited 15,482,756 H
|
||
Shares
|
||
5.55% 4.01% May 26, 2026
|
||
Nice Credit Limited 14,541,239 H
|
||
Shares
|
||
5.21% 3.77% May 26, 2026
|
||
Kaifeng Venture Capital Co., Ltd. (ࠬ
|
||
ʮ̡ )
|
||
12,805,764 H
|
||
Shares
|
||
4.59% 3.32% May 26, 2026
|
||
Tasly (Hong Kong) Pharmaceuticals
|
||
Limited ( ˂ɻɢ(ಥ)ʮ̡ )
|
||
12,740,586 H
|
||
Shares
|
||
4.56% 3.30% May 26, 2026
|
||
Shanghai Yaocui Investment Center
|
||
(Limited Partnership) ( ɪऎᓚയҳ༟ʕː
|
||
(Υྫ ))
|
||
12,213,941
|
||
(including
|
||
7,328,365 H
|
||
Shares)
|
||
2.63% 3.16% May 26, 2026
|
||
Suzhou Industrial Park Zhongxin Huiyuan
|
||
Investment Center (Limited Partnership)
|
||
(ᘽψʈุਜʕ㒥Ⴣҳ༟ʕː (ࠢ
|
||
Υྫ))
|
||
11,705,026
|
||
(including
|
||
1,017,828 H
|
||
Shares)
|
||
0.36% 3.03% May 26, 2026
|
||
|
||
|
||
--- page 10 ---
|
||
10
|
||
Name
|
||
Number
|
||
of Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued H
|
||
Shares subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued Shares
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (Note 1)
|
||
Share Link Capital Co., Ltd. 9,752,279 H
|
||
Shares
|
||
3.49% 2.53% May 26, 2026
|
||
Chelmsford International Limited 7,151,567 H
|
||
Shares
|
||
2.56% 1.85% May 26, 2026
|
||
Ms. Lin BAI (؍6,810,871 H
|
||
Shares
|
||
2.44% 1.76% May 26, 2026
|
||
Huzhou Qiyuan Zhixin Equity Investment
|
||
Partnership (Limited Partnership) ( ಳψ઼
|
||
ᛆҳ༟ΥྫΆุ (Υྫ ))
|
||
5,452,433
|
||
Unlisted
|
||
Shares
|
||
– 1.41% May 26, 2026
|
||
Suzhou Industrial Park Investment Fund
|
||
L.P. (ږ( ࠢ
|
||
Υྫ))
|
||
5,089,142
|
||
Unlisted
|
||
Shares
|
||
– 1.32% May 26, 2026
|
||
Suzhou Yipu II Equity Investment
|
||
Partnership (Limited Partnership) ( ᘽψᑈ
|
||
ᛆҳ༟ΥྫΆุ (Υྫ ))
|
||
4,839,104 H
|
||
Shares
|
||
1.73% 1.25% May 26, 2026
|
||
Pingtan Puxin Yingke Ruiyuan Venture
|
||
Capital Partnership (Limited Partnership)
|
||
(ြჃ௴ุҳ༟ΥྫΆุ
|
||
(Υྫ ))
|
||
4,455,203 H
|
||
Shares
|
||
1.60% 1.15% May 26, 2026
|
||
Asia Private Equity Capital 3,780,075 H
|
||
Shares
|
||
1.35% 0.98% May 26, 2026
|
||
Shihezi Xinyue Equity Investment
|
||
Enterprise (Limited Partnership) (ɿ
|
||
ᛆҳ༟ΥྫΆุ (Υྫ ))
|
||
3,201,273 H
|
||
Shares
|
||
1.15% 0.83% May 26, 2026
|
||
China-Singapore Suzhou Industrial Park
|
||
Industrial Investment Co., Ltd. ( ʕอᘽψ
|
||
ʮ̡ )
|
||
3,053,485 H
|
||
Shares
|
||
1.09% 0.79% May 26, 2026
|
||
Agricultural Bank II Wuxi Equity
|
||
Investment Center (Limited Partnership)
|
||
(ᛆҳ༟ʕː (Υྫ ))
|
||
3,053,485 H
|
||
Shares
|
||
1.09% 0.79% May 26, 2026
|
||
Wuxi Guolian Guokang Health Industry
|
||
Investment Center (Limited Partnership)
|
||
(ೌ፼ᑌੰੰପุҳ༟ʕː (ࠢ
|
||
Υྫ))
|
||
3,053,485
|
||
(including
|
||
1,526,743 H
|
||
Shares)
|
||
0.55% 0.79% May 26, 2026
|
||
|
||
|
||
--- page 11 ---
|
||
11
|
||
Name
|
||
Number
|
||
of Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued H
|
||
Shares subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued Shares
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (Note 1)
|
||
Suzhou KF Pegbio Venture Capital
|
||
Partnership (Limited Partnership) ( ᘽψ௱
|
||
௴ุҳ༟ΥྫΆุ (Υྫ ))
|
||
2,400,957 H
|
||
Shares
|
||
0.86% 0.62% May 26, 2026
|
||
Wuhan Taiming Venture Capital
|
||
Partnership (Limited Partnership) (ဏइ
|
||
௴ุҳ༟ΥྫΆุ (Υྫ ))
|
||
2,035,657
|
||
(including
|
||
1,017,829 H
|
||
Shares)
|
||
0.36% 0.53% May 26, 2026
|
||
Suzhou Ruihua Investment Partnership
|
||
(Limited Partnership) ( ᘽψശҳ༟Υྫ
|
||
Άุ(Υྫ ))
|
||
2,035,657 H
|
||
Shares
|
||
0.73% 0.53% May 26, 2026
|
||
CCB Sci-Tech (Suzhou) Investment and
|
||
Loan Linkage Equity Investment Fund
|
||
(Limited Partnership) (௴ (ᘽψ)ҳ
|
||
ږ( Υྫ ))
|
||
2,035,657 H
|
||
Shares
|
||
0.73% 0.53% May 26, 2026
|
||
Huaxin Securities Investment Co., Ltd.
|
||
(ʮ̡ )
|
||
2,035,657 H
|
||
Shares
|
||
0.73% 0.53% May 26, 2026
|
||
Beijing Lehe Century Technology Co.,
|
||
Ltd. (ʮ̡ )
|
||
2,035,656 H
|
||
Shares
|
||
0.73% 0.53% May 26, 2026
|
||
Zhoushan Wuyouen Enterprise
|
||
Management Consulting Partnership
|
||
(Limited Partnership) (Άุ၍
|
||
ଣፔ༔ΥྫΆุ (Υྫ ))
|
||
1,817,998 H
|
||
Shares
|
||
0.65% 0.47% May 26, 2026
|
||
Xi’an Jingsong Business Information
|
||
Consulting Partnership (Limited
|
||
Partnership) (ፔ༔Υ
|
||
ྫΆุ(Υྫ ))
|
||
1,526,743 H
|
||
Shares
|
||
0.55% 0.40% May 26, 2026
|
||
Suzhou Industrial Park Zhongxin
|
||
Hengxiang Investment Center (Limited
|
||
Partnership) (ୂҳ
|
||
༟ʕː(Υྫ ))
|
||
1,526,743
|
||
Unlisted
|
||
Shares
|
||
– 0.40% May 26, 2026
|
||
Suzhou Yuankang Dingxiang Investment
|
||
Management Partnership (Limited
|
||
Partnership) ( ᘽψჃੰཻୂҳ༟၍ଣΥ
|
||
ྫΆุ(Υྫ ))
|
||
1,526,743 H
|
||
Shares
|
||
0.55% 0.40% May 26, 2026
|
||
|
||
|
||
--- page 12 ---
|
||
12
|
||
Name
|
||
Number
|
||
of Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued H
|
||
Shares subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued Shares
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (Note 1)
|
||
Pingtan Yuanbo Kangjian Phase I Venture
|
||
Capital Partnership (Limited Partnership)
|
||
(௹ੰɓಂ௴ุҳ༟ΥྫΆุ
|
||
(Υྫ ))
|
||
1,017,828 H
|
||
Shares
|
||
0.36% 0.26% May 26, 2026
|
||
Suzhou Lanhu Zhuopu Venture
|
||
Investment Partnership (Limited
|
||
Partnership) ( ᘽψళಳՙዾ௴ุҳ༟Υ
|
||
ྫΆุ(Υྫ ))
|
||
1,017,828 H
|
||
Shares
|
||
0.36% 0.26% May 26, 2026
|
||
Connected Triumph Limited 849,289 H
|
||
Shares
|
||
0.30% 0.22% May 26, 2026
|
||
Suzhou Jinmao Enterprise Management
|
||
Consulting Co., Ltd. (Άุ၍ଣ
|
||
ʮ̡ )
|
||
800,317
|
||
(including
|
||
400,000 H
|
||
Shares)
|
||
0.14% 0.21% May 26, 2026
|
||
Mr. Hongfu XIE (˹) 727,199 H
|
||
Shares
|
||
0.26% 0.19% May 26, 2026
|
||
Shanghai Tongyuan Enterprise Consulting
|
||
Management Center (Limited Partnership)
|
||
(ɪऎஷʩΆุፔ༔၍ଣʕː (Υྫ ))
|
||
508,914 H
|
||
Shares
|
||
0.18% 0.13% May 26, 2026
|
||
Mr. Gang LU (508,914 H
|
||
Shares
|
||
0.18% 0.13% May 26, 2026
|
||
Mr. Anquan PENG ( ుτΌ) 363,600 H
|
||
Shares
|
||
0.13% 0.09% May 26, 2026
|
||
Ms. Liping LIU ( ᄎᘆറ) 354,509
|
||
(including
|
||
106,353 H
|
||
Shares)
|
||
0.04% 0.09% May 26, 2026
|
||
Mr. Tao XIE ( ᑽᏹ) 181,800 H
|
||
Shares
|
||
0.07% 0.05% May 26, 2026
|
||
Ms. Yu ZHANG ( ੵ◔) 181,800
|
||
(including
|
||
90,000 H
|
||
Shares)
|
||
0.03% 0.05% May 26, 2026
|
||
|
||
|
||
--- page 13 ---
|
||
13
|
||
Name
|
||
Number
|
||
of Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued H
|
||
Shares subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued Shares
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (Note 1)
|
||
Mr. Sujian SHAN (ܔ109,080
|
||
(including
|
||
54,540 H
|
||
Shares)
|
||
0.02% 0.03% May 26, 2026
|
||
Mr. Xiao WANG ( ˮᄟ) 90,900
|
||
(including
|
||
45,450 H
|
||
Shares)
|
||
0.02% 0.02% May 26, 2026
|
||
Mr. Jiangmin SHAN ( ఊϪს) 63,630
|
||
(including
|
||
31,815 H
|
||
Shares)
|
||
0.01% 0.02% May 26, 2026
|
||
Mr. Sumin SHAN ( ఊᘽს) 45,450
|
||
(including
|
||
22,725 H
|
||
Shares)
|
||
0.01% 0.01% May 26, 2026
|
||
Ms. Ying KUANG ( Ηᚱ) 45,450
|
||
(including
|
||
22,725 H
|
||
Shares)
|
||
0.01% 0.01% May 26, 2026
|
||
Sub-total 165,025,690
|
||
(including
|
||
133,922,500
|
||
H Shares)
|
||
47.97% 42.76%
|
||
Total 366,672,032
|
||
(including
|
||
259,880,839
|
||
H Shares)
|
||
93.09% 95.00%
|
||
Notes:
|
||
1. The expiry day of the lock-up period shown in the table above is pursuant to the PRC Company Law.
|
||
2. On April 2, 2021, Dr. Michael Min XU, Dr. Xiangjun ZHOU, Dr. Yuhong XU (ࠀand Shanghai Sujie (collectively,
|
||
the “Concert Parties ”) entered into a concert party agreement, pursuant to which they acknowledged and confirmed their
|
||
relationship of acting in concert as Shareholders when exercising the voting rights of the Company since they became
|
||
Shareholders, and agreed to continue such acting in concert relationship so long as they hold any Shares, unless termination is
|
||
agreed among all parties to the agreement. For more details, please refer to the paragraphs headed “History, Development and
|
||
Corporate Structure { Concert Party Agreement ” in the Prospectus.
|
||
|
||
|
||
--- page 14 ---
|
||
14
|
||
Name
|
||
Number
|
||
of Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued H
|
||
Shares subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued Shares
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (Note 1)
|
||
3. For more details on the background of Mingly, please refer to the paragraphs headed “History, Development and Corporate
|
||
Structure { Pre-IPO Investments { Information about our Pre-IPO Investors { Mingly ” in the Prospectus.
|
||
4. SIP BioVC, SIP VC II, SIP VC III and YuanBio are investment funds established by YuanBio Venture Capital ( ʩ͛௴ҳ ). For
|
||
more details, please refer to the paragraphs headed “History, Development and Corporate Structure { Pre-IPO Investments {
|
||
Information about our Pre-IPO Investors { YuanBio Venture Capital ” in the Prospectus.
|
||
5. The general partner of Hangzhou Tigermed is Shanghai Tigermed Technology Co., Ltd. (ʮ̡ ),
|
||
a company wholly owned by Hangzhou Tigermed Consulting Co., Ltd. (ʮ̡ ) ( “Tigermed
|
||
Consulting ”). Tigermed HK is wholly owned by Tigermed Consulting. The general partner of Hangzhou Taiyu is Hangzhou
|
||
Taiyu Investment Consulting Co., Ltd. (ʮ̡ ), which is controlled by Tigermed Consulting. For more
|
||
details, please refer to the paragraphs headed “History, Development and Corporate Structure { Pre-IPO Investments {
|
||
Information about our Pre-IPO Investors { Tigermed ” in the Prospectus.
|
||
6. Pingtan Yingke and Zibo Yingke share the same general partner, Yingke Innovation Asset Management Co., Ltd. (௴อ༟ପ
|
||
ʮ̡ ). For more details, please refer to the paragraphs headed “History, Development and Corporate Structure { Pre-
|
||
IPO Investments { Information about our Pre-IPO Investors { Yingke PE ” in the Prospectus.
|
||
7. Qianhai FoF is managed by Qianhai Ark Asset Management Co., Ltd. (ʮ̡ ) as its general partner, a
|
||
company which is ultimately controlled by Mr. Haitao JIN ( ◽ऎᏹ). The general partner of Zhongyuan Qianhai is Qianhai Ark
|
||
(Zhengzhou) Venture Capital Management Enterprise (Limited Partnership) (ऎ˙Ћ (ቍψ)௴ุҳ༟၍ଣΆุ (Υྫ )),
|
||
a limited partnership which is ultimately controlled by Mr. Haitao JIN. For more details, please refer to the paragraphs headed
|
||
“History, Development and Corporate Structure { Pre-IPO Investments { Information about our Pre-IPO Investors { Qianhai ”
|
||
in the Prospectus.
|
||
8. Beijing Agile is controlled by Mr. Jian CHEN ( ᄉ). For more details, please refer to the paragraphs headed “History,
|
||
Development and Corporate Structure { Pre-IPO Investments { Information about our Pre-IPO Investors { Beijing Agile ” in
|
||
the Prospectus.
|
||
9. For details on the background of other Pre-IPO Investors, please refer to the paragraphs headed “History, Development and
|
||
Corporate Structure { Pre-IPO Investments { Information about our Pre-IPO Investors ” in the Prospectus.
|
||
|
||
|
||
--- page 15 ---
|
||
15
|
||
Cornerstone Investor
|
||
Name
|
||
Number of
|
||
H Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued H
|
||
Shares subject
|
||
to lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued Shares
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (Note)
|
||
Yizekangrui 9,584,500 3.43% 2.48% November 26, 2025
|
||
Total 9,584,500 3.43% 2.48%
|
||
Note: The expiry day of the lock-up period shown in the table above is pursuant to the relevant Cornerstone
|
||
Investment Agreement.
|
||
PLACEE CONCENTRATION ANALYSIS
|
||
Placees*
|
||
Number of H
|
||
Shares allotted
|
||
Allotment
|
||
as % of
|
||
International
|
||
Offering
|
||
Allotment as %
|
||
of total Offer
|
||
Shares
|
||
Number of
|
||
Shares held
|
||
upon Listing
|
||
% of total
|
||
issued share
|
||
capital upon
|
||
Listing
|
||
Top 1 9,584,500 99.41% 49.70% 9,584,500 2.48%
|
||
Top 5 9,586,500 99.43% 49.71% 9,586,500 2.48%
|
||
Top 10 9,589,000 99.46% 49.73% 9,589,000 2.48%
|
||
Top 25 9,596,500 99.53% 49.77% 9,596,500 2.49%
|
||
Note:
|
||
* Ranking of placees is based on the number of Shares allotted to the placees.
|
||
|
||
|
||
--- page 16 ---
|
||
16
|
||
H SHAREHOLDER CONCENTRATION ANALYSIS
|
||
H Shareholders*
|
||
Number of H
|
||
Shares allotted
|
||
Allotment as %
|
||
of International
|
||
Offering
|
||
Allotment as % of
|
||
total Offer Shares
|
||
Number of H
|
||
Shares held upon
|
||
Listing
|
||
% of total issued
|
||
H share capital
|
||
upon Listing
|
||
Number of Shares
|
||
held upon Listing
|
||
Top 1 0 0.00% 0.00% 59,679,126 21.38% 100,336,438
|
||
Top 5 0 0.00% 0.00% 128,588,281 46.06% 186,671,630
|
||
Top 10 0 0.00% 0.00% 190,280,963 68.16% 248,364,312
|
||
Top 25 9,584,500 99.41% 49.70% 254,082,475 91.02% 317,051,400
|
||
Note:
|
||
* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholder upon Listing.
|
||
SHAREHOLDER CONCENTRATION ANALYSIS
|
||
Shareholders*
|
||
Number of H
|
||
Shares allotted
|
||
Allotment as %
|
||
of International
|
||
Offering
|
||
Allotment as % of
|
||
total Offer Shares
|
||
Number of H
|
||
Shares held upon
|
||
Listing
|
||
Number of Shares
|
||
held upon Listing
|
||
% of total issued
|
||
share capital
|
||
upon Listing
|
||
Top 1 0 0.00% 0.00% 59,679,126 100,336,438 26.00%
|
||
Top 5 0 0.00% 0.00% 128,588,281 186,671,630 48.37%
|
||
Top 10 0 0.00% 0.00% 176,004,235 251,512,870 65.17%
|
||
Top 25 9,584,500 99.41% 49.70% 245,556,719 347,359,071 90.00%
|
||
Note:
|
||
* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.
|
||
|
||
|
||
--- page 17 ---
|
||
17
|
||
BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING
|
||
Subject to the satisfaction of the conditions set out in the Prospectus, a total of 49,627 valid
|
||
applications made by the public will be conditionally allocated on the basis set out below:
|
||
Number of
|
||
H Shares
|
||
applied for
|
||
Number
|
||
of valid
|
||
applications Basis of allocation/ballot
|
||
Approximate %
|
||
allotted of the
|
||
total no. of H
|
||
Shares applied for
|
||
|
||
POOL A
|
||
|
||
500 18,543 1,483 out of 18,543 to receive 500 Shares 8.00%
|
||
1,000 4,139 414 out of 4,139 to receive 500 Shares 5.00%
|
||
1,500 2,155 217 out of 2,155 to receive 500 Shares 3.36%
|
||
2,000 1,699 180 out of 1,699 to receive 500 Shares 2.65%
|
||
2,500 1,235 133 out of 1,235 to receive 500 Shares 2.15%
|
||
3,000 1,421 162 out of 1,421 to receive 500 Shares 1.90%
|
||
3,500 498 58 out of 498 to receive 500 Shares 1.66%
|
||
4,000 485 58 out of 485 to receive 500 Shares 1.49%
|
||
4,500 351 43 out of 351 to receive 500 Shares 1.36%
|
||
5,000 2,638 330 out of 2,638 to receive 500 Shares 1.25%
|
||
6,000 1,095 138 out of 1,095 to receive 500 Shares 1.05%
|
||
7,000 871 110 out of 871 to receive 500 Shares 0.90%
|
||
8,000 535 68 out of 535 to receive 500 Shares 0.79%
|
||
9,000 344 45 out of 344 to receive 500 Shares 0.73%
|
||
10,000 2,478 330 out of 2,478 to receive 500 Shares 0.67%
|
||
15,000 1,507 279 out of 1,507 to receive 500 Shares 0.62%
|
||
20,000 1,167 283 out of 1,167 to receive 500 Shares 0.61%
|
||
25,000 824 246 out of 824 to receive 500 Shares 0.60%
|
||
30,000 716 253 out of 716 to receive 500 Shares 0.59%
|
||
35,000 451 182 out of 451 to receive 500 Shares 0.58%
|
||
40,000 383 174 out of 383 to receive 500 Shares 0.57%
|
||
45,000 267 134 out of 267 to receive 500 Shares 0.56%
|
||
50,000 882 481 out of 882 to receive 500 Shares 0.55%
|
||
60,000 504 324 out of 504 to receive 500 Shares 0.54%
|
||
70,000 368 271 out of 368 to receive 500 Shares 0.53%
|
||
80,000 301 249 out of 301 to receive 500 Shares 0.52%
|
||
90,000 215 196 out of 215 to receive 500 Shares 0.51%
|
||
100,000 895 500 Shares 0.50%
|
||
150,000 503 500 Shares plus 33 out of 503 to receive additional 500 Shares 0.36%
|
||
200,000 299 500 Shares plus 120 out of 299 to receive additional 500 Shares 0.35%
|
||
250,000 194 500 Shares plus 131 out of 194 to receive additional 500 Shares 0.34%
|
||
300,000 313 1,000 Shares 0.33%
|
||
48,276 Total number of Pool A successful applicants: 9,045
|
||
|
||
|
||
--- page 18 ---
|
||
18
|
||
Number of
|
||
H Shares
|
||
applied for
|
||
Number
|
||
of valid
|
||
applications Basis of allocation/ballot
|
||
Approximate %
|
||
allotted of the
|
||
total no. of H
|
||
Shares applied for
|
||
|
||
POOL B
|
||
350,000 674 3,000 Shares 0.86%
|
||
400,000 105 3,000 Shares plus 67 out of 105 to receive additional 500 Shares 0.83%
|
||
450,000 41 3,000 Shares plus 33 out of 41 to receive additional 500 Shares 0.76%
|
||
500,000 79 3,500 Shares 0.70%
|
||
550,000 47 3,500 Shares plus 7 out of 47 to receive additional 500 Shares 0.65%
|
||
600,000 33 3,500 Shares plus 17 out of 33 to receive additional 500 Shares 0.63%
|
||
650,000 32 4,000 Shares 0.62%
|
||
700,000 58 4,000 Shares plus 23 out of 58 to receive additional 500 Shares 0.60%
|
||
750,000 32 4,000 Shares plus 22 out of 32 to receive additional 500 Shares 0.58%
|
||
800,000 20 4,500 Shares 0.56%
|
||
850,000 24 4,500 Shares plus 8 out of 24 to receive additional 500 Shares 0.55%
|
||
964,000 206 5,000 Shares 0.52%
|
||
1,351 Total number of Pool B successful applicants: 1,351
|
||
As of the date of this announcement, the relevant subscription monies previously deposited in the
|
||
designated nominee accounts have been remitted back to the accounts of all HKSCC participants.
|
||
Investors should contact their relevant brokers for any inquiries.
|
||
COMPLIANCE WITH LISTING RULES AND GUIDANCE
|
||
The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of
|
||
which consent has been obtained, the Company has complied with the Listing Rules and guidance
|
||
materials in relation to the placing, allotment and listing of the H Shares.
|
||
The Directors confirm that, to the best of their knowledge, no rebate has been, directly or
|
||
indirectly, provided by the Company, Directors or syndicate members to any places or the public
|
||
(as the case may be) and the consideration paid by them for each Offer Share subscribed for or
|
||
purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC
|
||
transaction levy, SFC transaction levy and Stock Exchange trading fee payable.
|
||
OTHERS/ADDITIONAL INFORMATION
|
||
Reallocation
|
||
As the Hong Kong Public Offering has been oversubscribed by more than 100 times, the
|
||
reallocation as described in the section headed “Structure of the Global Offering – The Hong
|
||
Kong Public Offering – Reallocation ” of the Prospectus has been applied.
|
||
The number of Offer Shares initially available under the Hong Kong Public Offering is 1,928,500
|
||
H Shares, representing approximately 10% of the total number of Offer Shares available under
|
||
the Global Offering. As a result of such reallocation, the final number of Offer Shares under the
|
||
Hong Kong Public Offering is adjusted to 9,642,000 H Shares, representing approximately 50%
|
||
of the total number of Offer Shares available under the Global Offering.
|
||
|
||
|
||
--- page 19 ---
|
||
19
|
||
DISCLAIMERS
|
||
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and
|
||
Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this
|
||
announcement, make no representation as to its accuracy or completeness and expressly disclaim
|
||
any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or
|
||
any part of the contents of this announcement.
|
||
This announcement is not for release, publication, distribution, directly or indirectly, in or into
|
||
the United States (including its territories and possessions, any state of the United States and
|
||
the District of Columbia). This announcement does not constitute or form a part of any offer or
|
||
solicitation to purchase or subscribe for securities in the United States. The securities mentioned
|
||
herein have not been, and will not be, registered under the United States Securities Act of 1933,
|
||
as amended (the “U.S. Securities Act ”). The securities may not be offered or sold in the United
|
||
States except pursuant to an exemption from the registration requirements of the U.S. Securities
|
||
Act and in compliance with any applicable state securities laws, or outside the United States
|
||
unless in compliance with Regulation S under the U.S. Securities Act. There will be no public
|
||
offer of securities in the United States.
|
||
The Offer Shares are being offered and sold outside the United States in offshore transactions in
|
||
reliance on Regulation S under the U.S. Securities Act.
|
||
This announcement is for information purposes only and does not constitute an invitation or offer
|
||
to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential
|
||
investors should read the Prospectus dated May 19, 2025 issued by PegBio Co., Ltd. (ي
|
||
ᔼᖹ(ψ)ʮ̡ ) for detailed information about the Global Offering described below
|
||
before deciding whether or not to invest in the H Shares thereby being offered.
|
||
* Potential investors of the Offer Shares should note that the Sponsor-OC (for itself and on
|
||
behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the
|
||
Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the
|
||
events set out in the section headed “Underwriting { Underwriting Arrangements and Expenses
|
||
{ Hong Kong Public Offering { Grounds for Termination ” in the Prospectus at any time
|
||
prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on
|
||
Tuesday, May 27, 2025).
|
||
|
||
|
||
--- page 20 ---
|
||
20
|
||
PUBLIC FLOAT
|
||
Immediately following the completion of the Global Offering, an aggregate of 218,395,213 H
|
||
Shares, representing approximately 56.59% of the total issued share capital of the Company, will
|
||
be held in the public hands. Therefore, over 25% of the Company ’s total issued Shares will be
|
||
held by the public upon completion of the Global Offering, satisfying the minimum percentage
|
||
requirement in compliance with Rule 8.08(1)(a) of the Listing Rules. Based on the Offer Price of
|
||
HK$15.60 per Share, the Company will have a market capitalization of at least HK$375 million
|
||
held by the public at the time of the Listing as required under Rule 18A.07 of the Listing Rules.
|
||
The Directors confirm that, immediately following the completion of the Global Offering, (i)
|
||
no placee will, individually, be placed more than 10% of the enlarged issued share capital of
|
||
the Company immediately after the Global Offering; (ii) there will not be any new substantial
|
||
Shareholder immediately after the Global Offering; (iii) the three largest public Shareholders
|
||
do not hold more than 50% of the Shares held in the public hands at the time of the Listing in
|
||
compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300
|
||
Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.
|
||
COMMENCEMENT OF DEALINGS
|
||
The H Share certificates will only become valid evidence of title at 8:00 a.m. on Tuesday, May 27,
|
||
2025 (Hong Kong time), provided that the Global Offering has become unconditional and the right
|
||
of termination described in the paragraphs headed “Underwriting – Underwriting Arrangements
|
||
and Expenses – Hong Kong Public Offering – Grounds for Termination ” in the Prospectus has
|
||
not been exercised. Investors who trade the H Shares on the basis of publicly available allocation
|
||
details prior to the receipt of H Share certificates or prior to the H Share certificates becoming
|
||
valid evidence of title do so entirely at their own risk.
|
||
Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Tuesday, May
|
||
27, 2025 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange
|
||
will commence at 9:00 a.m. on Tuesday, May 27, 2025 (Hong Kong time).
|
||
The H Shares will be traded in board lots of 500 H Shares each, and the stock code of the H Shares
|
||
will be 2565.
|
||
By order of the Board
|
||
PegBio Co., Ltd.
|
||
Michael Min XU
|
||
Chairman of the Board, Executive Director and General Manager
|
||
Hong Kong, May 26, 2025
|
||
As of the date of this announcement, the board of directors of the Company comprises: (i) Dr.
|
||
Michael Min XU and Ms. Xiaojun WANG as executive directors; (ii) Dr. Xiangjun ZHOU, Dr.
|
||
Yuhong XU, Ms. Ting ZHAI and Mr. Hongkai LI as non-executive directors; and (iii) Dr. Jiancun
|
||
ZHANG, Dr. Yangyang CHEN and Ms. Xinpeng FAN as independent non-executive directors.
|